- ClinicalTrials.gov ID: NCT04004065
- Not accepting healthy volunteers
- UTSW Principal Investigator: SUSAN THERESA IANNACCONE
objective
To evaluate the safety and tolerability of multiple ascending doses of SRP-5051 (4 mg/kg, 10 mg/kg, 20 mg/kg, and 30 mg/kg), administered intravenously (IV) every 4 weeks, and determine the maximum tolerated dose (MTD); To evaluate dystrophin protein level in skeletal muscle tissue following SRP-5051 treatment, administered IV every 4 weeks at the doses selected based on data from Part A